Application of oxygen-bridged bicyclo-[2.2.1]-heptene compounds in the preparation of drugs against novel coronavirus
By developing oxygen-bridge bicyclic-[2.2.1]-heptene compounds containing different side chain structures, the convenience of existing anti-novel coronavirus drugs and the efficacy of mutant strains on existing drugs have been solved, and effective new types have been achieved Coronavirus inhibitory effect.
Patent Information
- Application Number
- CN202211532996.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-01
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-12-01
AI Technical Summary
Most of the existing anti-novel coronavirus drugs are intravenous forms, which cannot meet the needs of oral convenience. Moreover, due to the emergence of the mutant strain of the novel coronavirus, there is an urgent need to develop new, low-toxic and efficient small-molecule inhibitors for the novel coronavirus.
Develop oxygen-bridged bicyclic-[2.2.1]-heptene-based compounds containing different side chain structures, including basic side chains, alkyl side chains, resveratrol and covalent inhibitor structures-[2.2. 1]-Heptene compounds, used to prepare anti-novel coronavirus drugs.
These compounds have shown to effectively inhibit the activity of the novel coronavirus and are less cytotoxic. They can be used to prepare anti-novo coronavirus drugs, especially with broad-spectrum inhibitory activities for a variety of viral variants, providing new therapeutic options.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology and relates to a bicyclic-[2.2.1]-heptene compound containing oxygen bridges with different side chain structures and its application in the preparation of anti-new coronavirus drugs. Background Art
[0002] Coronavirus is a large family of viruses known to cause colds and more serious diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). From a systematic taxonomic perspective, coronavirus belongs to the Nidovirales order, the Coeonaviridase family, and the Coronavirus genus. It is a linear single-stranded positive-sense RNA virus. According to the different serological and genetic composition characteristics, coronaviruses can be divided into four genera, including: α, β, γ and δ coronavirus genera. SARS-CoV-2 belongs to the β coronavirus genus and has a typical coronavirus morphology. The virus particles are round or oval, polymorphic, 60-140 nm in diameter, and the full length of the genome is about 30kb. It is an enveloped RNA virus with a linear single-stranded positive-sense genome. The particles are round or oval and about 60-140nm in diameter.
[0003] At present, there are three anti-new coronavirus drugs approved by the US FDA, Remdesivir, Molnupiravir, and Paxlovid. Remdesivir can only be administered by intravenous injection, which cannot meet the demand for more convenient oral antiviral drugs in treatment. Both Molnupiravir and Remdesivir are RNA polymerase (RdRp) inhibitors, that is, they both target RdRp. The new coronavirus is an RNA virus, and RNA-dependent RNA polymerase (RdRps) is a key enzyme for the replication and transcription of RNA viral genetic material. RdRp is therefore considered to be one of the most promising targets for the development of anti-RNA virus drugs. Molnupiravir shows consistent efficacy in different viral variants Gamma, Delta, and Mu. Paxlovid is a proteasome inhibitor that needs to be used when patients have early symptoms of infection. By binding to viral enzymes, the new coronavirus can be prevented from replicating in cells. In addition, the new crown monoclonal neutralizing antibody ambavir monoclonal antibody / romisvir monoclonal antibody combination therapy (previously known as BRII-196 / BRII-198 combination therapy) has been approved for emergency marketing by the China National Medical Products Administration (NMPA). However, due to the emergence of new coronavirus mutants, the development of new, low-toxic, and highly effective small molecule inhibitors against the new coronavirus is particularly urgent. Summary of the invention
[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a bicyclo-[2.2.1]-heptene compound containing oxygen bridges with different side chain structures and its application in the preparation of anti-new coronavirus drugs.
[0005] In order to achieve the above object, the technical solution adopted by the present invention is as follows:
[0006] The present invention finds that bicyclo-[2.2.1]-heptene compounds containing oxygen bridges with different side chain structures have anti-new coronavirus activity and are applicable to the preparation of anti-new coronavirus drugs.
[0007] The oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing different side chain structures include: oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing basic side chains, oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing alkyl side chains, oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing resveratrol (RES), and oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing covalent inhibitors.
[0008] The oxygen-bridged bicyclo-[2.2.1]-heptene-type structural compounds containing basic side chains include the following compounds A1-A29:
[0009]
[0010]
[0011] The preparation of the above-mentioned compounds A1-A29 can be found in the patent publication number CN109942595A "Oxygen-bridged bicyclic-[2.2.1]-heptene compounds containing different functional side chain structures and their preparation and application".
[0012] The oxygen-bridged bicyclo-[2.2.1]-heptene-type compounds containing alkyl side chains include the following compounds B1a-B13a, B1b-B13b, B14-B16:
[0013] B1a-13a:
[0014]
[0015] B1b-13b:
[0016]
[0017] B14-B16:
[0018]
[0019] The preparation of the above compounds B1a-13a, B1b-B13b, and B14-B16 can be found in the patent publication number CN108864127A "An oxygen-bridged bicyclic heptene sulfonamide compound containing different alkyl chain lengths, its preparation method and application".
[0020] The resveratrol-containing oxygen-bridged bicyclo-[2.2.1]-heptene-type structural compounds include the following compounds C1-C21:
[0021] C1-21:
[0022]
[0023]
[0024] The preparation of the above compounds C1-C21 is described in the patent publication number CN107188896A, "An oxygen-bridged bicycloheptene compound containing a resveratrol group and its preparation and use method".
[0025] The oxygen-bridged bicyclo-[2.2.1]-heptene-type compounds containing a covalent structure include the following compounds D1-D27:
[0026]
[0027]
[0028]
[0029] The preparation of the above compounds D1-D27 is described in the patent publication number CN113582949A, "An oxygen-bridged bicyclic-[2.2.1]-heptene compound containing different covalent warhead structures and its preparation and application".
[0030] In a first aspect, the present invention provides the use of the above-mentioned oxygen-bridged bicyclo-[2.2.1]-heptene compounds in the preparation of drugs against the new coronavirus.
[0031] In a second aspect, the present invention provides the use of pharmacologically or physiologically acceptable salts of the above-mentioned oxygen-bridged bicyclo-[2.2.1]-heptene compounds in the preparation of drugs against the new coronavirus.
[0032] In a third aspect, the present invention provides a pharmaceutical composition for use against the novel coronavirus, comprising at least one of the above-mentioned oxygen-bridged bicyclo-[2.2.1]-heptene compounds or a pharmacologically or physiologically acceptable salt thereof. Furthermore, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.
[0033] In a fourth aspect, the present invention provides the use of the above-mentioned oxygen-bridged bicyclo-[2.2.1]-heptene compounds or their pharmacologically or physiologically acceptable salts in the fight against the new coronavirus for non-disease treatment purposes.
[0034] The present invention relates to bicyclic-[2.2.1]-heptene compounds containing oxygen bridges with different side chain structures, which can effectively inhibit the activity of the new coronavirus, have low toxicity to cells, and can be used to prepare drugs against the new coronavirus. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 This is the result of the activity of compound A1-29 against the new coronavirus SARS-Cov-2 in Example 1. In the figure, NC is a negative control and M is a blank control group that is not infected with the virus.
[0036] Figure 2 This is the result of the activity of compounds B1a-B13a, B1b-B13b, and B14-16 in Example 1 against the new coronavirus SARS-Cov-2.
[0037] Figure 3 This is the result of the activity of compounds C1-C21 in Example 1 against the new coronavirus SARS-Cov-2.
[0038] Figure 4 This is the result of the activity of compounds D1-D27 in Example 1 against the new coronavirus SARS-Cov-2.
[0039] Figure 5 The results of Example 2. A is a graph showing the inhibitory activity of compound A6 against the novel coronavirus SARS-Cov-2, and B is a bar graph showing the inhibition rate of compound A6 against the novel coronavirus SARS-Cov-2 at different concentrations, where Remd is the control drug remdesivir. C is a graph showing the inhibitory activity of compound A14 against the novel coronavirus SARS-Cov-2, and D is a bar graph showing the inhibition rate of compound A14 against the novel coronavirus SARS-Cov-2 at different concentrations, where Remd is the control drug remdesivir.
[0040] Figure 6The results of Example 3. A is the inhibition rate of compound A6 against SARS-Cov-2 at 0.6µM and 0.005µM, and the control drug is remdersivir; Figure B is the inhibition rate of compound A6 against novel coronavirus variants (Alpha, Beta, Gamma, Nigeria, Deita, and Omicron) at concentrations of 2ng / µL and 10ng / µL. C is the inhibition rate of compound A14 against SARS-Cov-2 at 0.7µM and 0.006µM, and the control drug is remdersivir. Figure D is the inhibition rate of compound A14 against novel coronavirus variants (Alpha, Beta, Gamma, Nigeria, Deita, and Omicron) at concentrations of 2ng / µL and 10ng / µL. DETAILED DESCRIPTION
[0041] The features and advantages of the present invention can be further understood through the following detailed description. The examples provided are only applications of the method of the present invention and do not limit the remaining contents disclosed by the present invention in any way.
[0042] Example 1 In vitro anti-novel coronavirus activity test of oxygen-bridged bicyclic-[2.2.1]-heptene compounds
[0043] (1) Calu3 cells were plated in 24-well plates one day in advance. The experiment was performed at a cell density of 100%. The drug was diluted with DMSO to different concentrations (such as 0.1 mg / mL, 1 mg / mL, 10 mg / mL, 1 ng / µL, 2 ng / µL and 10 ng / µL), and 5 µL was added to each well. SARS-Cov-2, as well as mutants such as alpha, beta, gamma, Nigerian, delta and Omicron were infected at an MOI of 0.02. After culturing for 24 hours at 37°C and 5% CO2, the culture medium containing the virus and drug was removed. Wash once with PBS and add 500 µL TRIZOL to each well.
[0044] (2) Transfer TRIZOL in the well plate to a 1.5mL EP tube, add 100µL chloroform to each tube, cover the EP tube cap, shake vigorously for 15 seconds, place at room temperature (15-30°C) for 2-3 minutes, and centrifuge at 4°C, 12000g for 15 minutes; take the upper aqueous phase and place it in a new EP tube, add 250µL isopropanol, place at room temperature (15-30°C) for 10 minutes, and centrifuge at 4°C, 12000g for 10 minutes; discard the supernatant, add 500µL 75% ethanol for washing, vortex mix, centrifuge at 4°C, 7500g for 5 minutes, and discard the supernatant; let the precipitated RNA dry naturally at room temperature; dissolve the RNA precipitate with RNase-free water. Then reverse transcribe the RNA, dilute the obtained DNA, perform qPCR detection, and detect the fluorescence value by an enzyme marker. The fluorescence value is positively correlated with the amount of viral infection. The qPCR primers include: F: TAATCAGACAAGGAACTGATTA, R: CGAAGGTGTGACTTCCATG.
[0045] The four series of oxygen-bridged bicyclo-[2.2.1]-heptene compounds of the present invention were preliminarily screened for their activity against the novel coronavirus SARS-Cov-2. The results are shown in Figure 1-4 . Most of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing basic side chains have good anti-new coronavirus SARS-Cov-2 activity, such as compounds A6 and A14, etc., especially compounds A6 and A14 showed good anti-new coronavirus activity at 2ng / µL and 10ng / µL. Most of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing alkyl side chains have good anti-new coronavirus activity, such as compounds B6a, B11a, B15 and B16, etc., especially compounds B6a and B15 showed good anti-new coronavirus activity at 2ng / µL. Most of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing RES side chains have good anti-new coronavirus activity, such as compounds C4, C45, C10, etc., especially compound C4 showed good anti-new coronavirus activity at 2ng / µL. Most of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds containing covalent structures have good anti-novel coronavirus activity, such as compounds D13, D22-D24, etc., especially compound D23, which showed good anti-novel coronavirus activity at 2ng / µL.
[0046] Example 2 Compounds A6 and A14 against the new coronavirus IC 50 Test
[0047] According to the method of in vitro anti-new coronavirus SARS-Cov-2 activity in Example 1, the IC values of compounds A6 and A14 against the new coronavirus were detected.50 .
[0048] The experimental results are as follows Figure 5 The results showed that compounds A6 and A14 had inhibitory activity against the novel coronavirus SARS-Cov-2 in vitro, and IC 50 1.08µM and 1.14µM respectively.
[0049] Example 3 Broad-spectrum antiviral detection of compounds A6 and A14 against the new coronavirus
[0050] According to the in vitro anti-new coronavirus activity method in Example 1, the inhibitory activity of compounds A6 and A14 against different new coronaviruses was detected. Figure 6 ) showed that compounds A6 and A14 could achieve 50% or more inhibitory activity against a variety of new coronaviruses, such as SARS-Cov-2 and its variants Alpha, Beta, Gamma, Nigeria, Delta and Omicron at 10ng / µL and 2ng / µL.
[0051] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. Application of oxygen-bridged bicyclo-[2.2.1]-heptene compounds in the preparation of drugs against novel coronavirus; Features: The oxygen-bridged bicyclo-[2.2.1]-heptene compounds include: oxygen-bridged bicyclo-[2.2.1]-heptene compounds with basic side chains, oxygen-bridged bicyclo-[2.2.1]-heptene compounds with alkyl side chains, oxygen-bridged bicyclo-[2.2.1]-heptene compounds with resveratrol, and oxygen-bridged bicyclo-[2.2.1]-heptene compounds with covalent structures. The oxygen-bridged bicyclo-[2.2.1]-heptene-type structural compounds containing basic side chains include the following compounds: The oxygen-bridged bicyclo-[2.2.1]-heptene-type structural compounds containing alkyl side chains include the following compounds: The resveratrol-containing oxygen-bridged bicyclo-[2.2.1]-heptene-type structural compounds include the following compounds: The oxygen-bridged bicyclo-[2.2.1]-heptene-type structural compounds containing a covalent structure include the following compounds: 。 2. The use of the oxygen-bridged bicyclic-[2.2.1]-heptene compound according to claim 1 in the preparation of anti-new coronavirus drugs, Features: The oxygen-bridged bicyclo-[2.2.1]-heptene compound is selected from compounds A1, A2, A3, A5, A6, A7, A10, A13, A14, A15, A17, A18, A19, A23, A24, A26, A27, A28, and A29.
3. The use of the oxygen-bridged bicyclo-[2.2.1]-heptene compound according to claim 1 in the preparation of anti-new coronavirus drugs, Features: The oxygen-bridged bicyclo-[2.2.1]-heptene compound is selected from compounds B1b, B2a, B6a, and B11a.
4. The use of the oxygen-bridged bicyclo-[2.2.1]-heptene compound according to claim 1 in the preparation of anti-new coronavirus drugs, Features: The oxygen-bridged bicyclo-[2.2.1]-heptene compound is selected from compounds C4, C5, C7, C9, C10, and C14.
5. The use of the oxygen-bridged bicyclo-[2.2.1]-heptene compound according to claim 1 in the preparation of anti-new coronavirus drugs, Features: The oxygen-bridged bicyclo-[2.2.1]-heptene compound is selected from compounds D3, D4, D5, D11, D14, D15, D17, D22, and D25.
6. Use of a pharmacologically or physiologically acceptable salt of an oxygen-bridged bicyclo-[2.2.1]-heptene compound as described in any one of claims 1 to 5 in the preparation of a drug against the new coronavirus.
7. Use of the oxygen-bridged bicyclo-[2.2.1]-heptene compounds described in any one of claims 1 to 5 in the fight against the new coronavirus for non-disease treatment or prevention purposes.
8. Use of the salt described in claim 6 in anti-new coronavirus for non-disease treatment or prevention purposes.
